PDX Model

MSK-LX55

Sex: Male

Histology: Adenocarcinoma

Key Mutations: EML4-ALK Fusion

Molecular Characteristics: Yes

Matched Normal: Yes

Treatment: crizotinib

Site: Lung

Paired: No

Comments: crizotinib resistant

Licensing Information: Corporations and other for-profit entities may nonexclusively license Memorial Sloan Kettering’s tangible materials for research or commercial purposes.

MSK Office of Technology Development Contact: Alexandra Buga, MS, MBA, Licensing Associate, T: 646-888-1078, e-mail: bugaa@mskcc.org.

Stage of Development

Ready to use

Indications